Market Place
Sourcing Support
Trevi Therapeutics Reports Q3 2024 Results & Business Updates
06 Nov 2024 //
PR NEWSWIRE
Trevi Completes Enrollment For Phase 2a RIVER Cough Trial in Cough
21 Oct 2024 //
PR NEWSWIRE
Trevi Therapeutics Appoints James V. Cassella As CDO
30 Sep 2024 //
PR NEWSWIRE
Trevi To Present CANAL Trial Data At CHEST 2024
26 Sep 2024 //
PR NEWSWIRE
Trevi Therapeutics to Present Ph2a CANAL Trial Data at European Congress
04 Sep 2024 //
PR NEWSWIRE
Trevi Therapeutics to Participate in September Investor and Medical Conferences
28 Aug 2024 //
PR NEWSWIRE
Trevi Therapeutics Reports Q2 2024 Results And Reaffirms Trial Guidance
08 Aug 2024 //
PR NEWSWIRE
Trevi Therapeutics To Report Q2 2024 Results On August 8
01 Aug 2024 //
PR NEWSWIRE
Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events
02 Jul 2024 //
PR NEWSWIRE
Trevi Therapeutics to Participate in Upcoming Conferences
09 May 2024 //
PR NEWSWIRE
Trevi Therapeutics Q1 2024 Results, Business Updates
07 May 2024 //
PR NEWSWIRE
Trevi Therapeutics to Participate in Upcoming April Events
04 Apr 2024 //
PR NEWSWIRE
Trevi Adds Clinical Development Expertise in Chronic Cough to Leadership Team
02 Apr 2024 //
PR NEWSWIRE
Trevi Adds Clinical Devp Expertise in Chronic Cough to Leadership Team
02 Apr 2024 //
BIOSPACE
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results
20 Mar 2024 //
PR NEWSWIRE
Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results
13 Mar 2024 //
PR NEWSWIRE
Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Conference
06 Feb 2024 //
PR NEWSWIRE
Trevi Therapeutics Announces Third Quarter 2023 Financial Results
09 Nov 2023 //
PR NEWSWIRE
Trevi Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio
02 Nov 2023 //
PR NEWSWIRE
Trevi Therapeutics Announces Results from Phase 2b/3 Study of Haduvio
13 Oct 2023 //
PR NEWSWIRE
Trevi Therapeutics to Participate in Upcoming September Events
06 Sep 2023 //
PR NEWSWIRE
Trevi Therapeutics Announces Second Quarter 2023 Financial Results
10 Aug 2023 //
PR NEWSWIRE
Trevi Therapeutics to Report Q2 2023 Financial Results
03 Aug 2023 //
PR NEWSWIRE
Trevi Therapeutics to Participate in Upcoming August Events
01 Aug 2023 //
PR NEWSWIRE
Trevi Therapeutics to Participate in Upcoming June Conferences
30 May 2023 //
PR NEWSWIRE
Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial
22 May 2023 //
PR NEWSWIRE
Trevi Therapeutics Announces 1Q 2023FYR &Provides Business Update
11 May 2023 //
PR NEWSWIRE
Trevi Therapeutics to Report Q1 2023 Financial Results & & a Corporate Update
04 May 2023 //
PR NEWSWIRE
Trevi Therapeutics Announces Two Presentations on the Phase 2 CANAL
02 May 2023 //
PR NEWSWIRE
Trevi to Participate in the 22nd Annual Needham Virtual Healthcare Conference
11 Apr 2023 //
PR NEWSWIRE
Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results
16 Mar 2023 //
PR NEWSWIRE
Trevi Therapeutics to Participate in Upcoming March Conferences
06 Mar 2023 //
PR NEWSWIRE
Trevi to Present Conferences During the 41st Annual J.P. Morgan Conference
19 Dec 2022 //
PRNEWSWIRE
Trevi Therapeutics Appoints Pharma Industry Veteran as CMO
14 Nov 2022 //
PRNEWSWIRE
Trevi Therapeutics Announces Third Quarter 2022 FYR and Provides Business Update
10 Nov 2022 //
PRNEWSWIRE
Trevi Therapeutics to Participate at the Stifel 2022 Healthcare Conference
08 Nov 2022 //
PRNEWSWIRE
Trevi Therapeutics Announces Proposed Public Offering
22 Sep 2022 //
PRNEWSWIRE
Trevi Therapeutics Announces Pricing of $[50 Million] Public Offering
22 Sep 2022 //
PRNEWSWIRE
Trevi reports positive Phase II data of Haduvio for chronic cough in IDF
19 Sep 2022 //
CLINICALTRIALSARENA
Trevi to Present at H.C. Wainwright 24th Annual Global Investment Conference
07 Sep 2022 //
PRNEWSWIRE
Trevi Therapeutics to Host Virtual R&D Day on September 19, 2022
30 Aug 2022 //
PRNEWSWIRE
Trevi Tx Announces Multiple Late-Breaking Abstracts Accepted for Presentation
24 Aug 2022 //
PRNEWSWIRE
Trevi Therapeutics Announces Q2 2022 Rusult and Business Update
11 Aug 2022 //
PRNEWSWIRE
Trevi Therapeutics to Present at Upcoming August Conferences
09 Aug 2022 //
PRNEWSWIRE
Trevi Therapeutics to Report Q2 2022 Financial Results
04 Aug 2022 //
PRNEWSWIRE
Trevi Tx Reports Positive Results from the PIIb/III PRISM Trial of Haduvio
29 Jun 2022 //
PRNEWSWIRE
Trevi to Present and Participate in Partnership Meetings at Upcoming 2022 BIO
07 Jun 2022 //
PRNEWSWIRE
Trevi Therapeutics Announces First Quarter 2022 Financial Results
12 May 2022 //
PRNEWSWIRE
Trevi Therapeutics to Report Q1 2022 Financial Results
05 May 2022 //
PRNEWSWIRE
Trevi Therapeutics Announces $55 Million Private Placement Priced At-the-Market
07 Apr 2022 //
PRNEWSWIRE
Trevi Therapeutics to Participate at Needham Healthcare Conference
05 Apr 2022 //
PRNEWSWIRE
Trevi Tx Hosting Key Opinion Leader Webinar on Chronic Cough in IPF
22 Mar 2022 //
PRNEWSWIRE
Trevi Tx says Q4 and Year End 2021 Financial Results and Business Update
17 Mar 2022 //
PRNEWSWIRE
Trevi Tx Concludes Enrollment for P 2 CANAL Trial in IPF Chronic Cough
15 Mar 2022 //
PRNEWSWIRE
Trevi revs up extended-release opioid cough program
01 Mar 2022 //
FIERCEPHARMA
Trevi Tx Completes Enrollment for Phase 2b/3 PRISM Study in Chronic Pruritus
01 Feb 2022 //
PRNEWSWIRE
Trevi Therapeutics Announces Q3 2021 Financial Results and Business Update
10 Nov 2021 //
PRNEWSWIRE
Trevi Therapeutics Announces $11.8M Private Placement Priced At-the-Market
30 Sep 2021 //
PRNEWSWIRE
Trevi Therapeutics Announces Second Quarter 2021 Financial Results
12 Aug 2021 //
PRNEWSWIRE
Trevi Therapeutics Provides Clinical Trial Updates for Haduvio™
21 Oct 2020 //
GLOBENEWSWIRE
